Related Experiment Video
Updated: Feb 10, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Molecular drivers of metastatic castrate-resistant prostate cancer: New roads to resistance
Phoebe A Huang1, Douglas K Price1, William D Figg1
1a Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda , MD , USA.
Abstract:
Numerous growth-inducing signaling pathways have been implicated in the development of metastatic castrate-resistant prostate cancer, but their cross-talk with androgen receptor functions remains poorly understood. A recent study published in Science Signaling by Chen et al. 1 has identified a novel androgen-mediated signaling axis driven by loss of SPDEF and gain of TGFBI to facilitate metastasis, which may explain the acquisition of resistance to androgen deprivation therapy. These findings suggest that therapeutic inhibition of androgen signaling may inadvertently promote castrate resistance by inhibiting tumor suppressive functions of the androgen receptor.
Insights
Loss of SPDEF and gain of TGFBI drives metastatic castrate-resistant prostate cancer (mCRPC) via a novel androgen-mediated axis. Inhibiting androgen signaling may paradoxically promote mCRPC by suppressing tumor-suppressive androgen receptor functions.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Metastatic castrate-resistant prostate cancer (mCRPC) involves complex signaling pathways.
- The interplay between growth signaling and androgen receptor (AR) function in mCRPC is not fully understood.
- Androgen deprivation therapy (ADT) is a standard treatment, but resistance mechanisms are critical.
Purpose of the Study:
- To elucidate novel signaling mechanisms driving mCRPC progression.
- To investigate the role of SPDEF and TGFBI in AR signaling and metastasis.
- To understand how AR function influences resistance to ADT.
Main Methods:
- Analysis of signaling pathways in prostate cancer models.
- Investigating the functional roles of SPDEF and TGFBI.
- Studying the impact of androgen receptor signaling on metastasis and therapy resistance.
Main Results:
- A novel androgen-mediated signaling axis involving loss of SPDEF and gain of TGFBI was identified.
- This axis promotes metastasis in prostate cancer.
- The findings suggest that SPDEF loss and TGFBI gain contribute to resistance to androgen deprivation therapy.
- Androgen receptor signaling plays a complex role, with potential tumor-suppressive functions.
Conclusions:
- The identified SPDEF/TGFBI axis represents a new mechanism in mCRPC development.
- Therapeutic strategies targeting androgen signaling need careful consideration due to potential adverse effects on AR tumor-suppressive functions.
- Understanding this axis may lead to improved treatments for advanced prostate cancer.
Related Concept Videos
Treatment Resistant Cancers
Resistivity
Resistance
Equivalent Resistance
Resistance and Conductance
Various factors impact the resistance of a conductor. Spiraling in stranded conductors increases their...
Rolling Resistance
For instance, imagine a hard cylinder rolling on a comparatively soft surface. The cylinder's weight compresses the surface beneath it. As the cylinder moves, the material in front of it slows down due to...

